更新于：2024-11-01

Hyperlipoproteinemia Type V

V型高脂蛋白血症

更新于：2024-11-01

基本信息

别名

5ｶﾞﾀｺｳｼｹｯｼｮｳ、5ｶﾞﾀｺｳｼｹﾂｼｮｳ、5ｶﾞﾀｺｳﾘﾎﾟﾀﾝﾊﾟｸｹｯｼｮｳ

+ [86]

简介

A severe type of hyperlipidemia, sometimes familial, that is characterized by the elevation of both plasma CHYLOMICRONS and TRIGLYCERIDES contained in VERY-LOW-DENSITY LIPOPROTEINS. Type V hyperlipoproteinemia is often associated with DIABETES MELLITUS and is not caused by reduced LIPOPROTEIN LIPASE activity as in HYPERLIPOPROTEINEMIA TYPE I .

关联

项与 V型高脂蛋白血症相关的药物

Simvastatin

辛伐他汀

靶点

HMG-CoA reductase

作用机制

HMG-CoA reductase抑制剂

在研机构

Organon & Co. [+3]

原研机构

Merck Sharp & Dohme Corp.

在研适应症

高胆固醇血症 [+6]

非在研适应症

急性冠状动脉综合征 [+7]

最高研发阶段批准上市

首次获批国家/地区

澳大利亚

首次获批日期1991-09-12

Recaticimab

瑞卡西单抗

靶点

PCSK9

作用机制

PCSK9抑制剂

在研机构

原研机构

在研适应症

非在研适应症

最高研发阶段申请上市

首次获批国家/地区-

首次获批日期1800-01-20

Anacetrapib

安塞曲匹

靶点

CETP

作用机制

CETP抑制剂

在研机构-

原研机构

Merck Sharp & Dohme Corp.

在研适应症-

非在研适应症

动脉粥样硬化 [+11]

最高研发阶段终止

首次获批国家/地区-

首次获批日期1800-01-20

项与 V型高脂蛋白血症相关的临床试验

NCT05088759 / Active, not recruitingN/AIIT

Randomized Controlled Trial of Alert-Based Computerized Decision Support for Optimizing Low-Density Lipoprotein Management (LDL-ALERT)

A 400-patient U.S.-based single-center Quality Improvement Initiative in the form of a randomized controlled trial focused on the feasibility of implementation of this electronic alert-based CDS (EPIC BPA) based on LDL-C values. The 400 patients will be comprised of 200 in the "Hospitalized Patient Cohort" and 200 in the "Outpatient Clinic Cohort." The allocation ratio will be 1:1 for an electronic alert-based CDS (EPIC BPA) notification versus no notification.

开始日期2021-10-08

申办/合作机构

The Brigham & Women's Hospital, Inc.

NCT05085184 / Unknown status临床1期

A Randomized, Open, Single-dose, 2x2x4 Replicate Crossover-design Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics After Co-administration of UIC201806 and UIC201602 or Administration of UI018 in Healthy Volunteers

This Study is to evaluate the safety and pharmacokinetics of a fixed dose combination formulation and co-administration.

开始日期2021-09-06

申办/合作机构

KOREA UNITED PHARM, Inc.

NCT04849000 / Completed临床3期

Phase III, Multicentre, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Efficacy and Safety of SHR-1209 Monotherapy in Patients With Primary Hypercholesterolemia and Mixed Hyperlipemia

The study is ongoing to evaluate the efficacy and safety of SHR-1209 in patients with hypercholesterolemia and hyperlipemia.

开始日期2021-04-23

申办/合作机构

江苏恒瑞医药股份有限公司

100 项与 V型高脂蛋白血症相关的临床结果

登录后查看更多信息

100 项与 V型高脂蛋白血症相关的转化医学

登录后查看更多信息

0 项与 V型高脂蛋白血症相关的专利（医药）

登录后查看更多信息

272

项与 V型高脂蛋白血症相关的文献（医药）

2023-07-05·Cureus

A Case of Type V Hyperlipoproteinemia Resistant to Insulin Treatment

作者: Alhuarrat, Majd Al Deen ; Faillace, Robert T ; Borkowski, Pawel ; Varrias, Dimitrios ; Kishore, Preeti ; Spanos, Michail ; Mangeshkar, Shaunak ; Nazarenko, Natalia ; Li, Weijia

Type V hyperlipoproteinemia or multifactorial chylomicronemia syndrome is a rare lipid disorder triggered mainly by uncontrolled diabetes, obesity, poor diet, or particular medications. It is associated with an increased risk of acute pancreatitis and accelerated coronary artery disease which may manifest in younger age groups. We present a case of a 42-year-old male who presented to the emergency department (ED) complaining of a non-healing hand injury. Upon laboratory workup, the patient was found to have an elevated total cholesterol (TC) of 1129 mg/dL, very low levels of high-density lipoprotein (HDL) and triglycerides (TG) > 4000 mg/dL with an inability to calculate low-density lipoprotein (LDL). Lipoprotein electrophoresis revealed an actual TG level of > 7000 mg/dL, increased chylomicrons, normal B and pre-B-lipoproteins, and increased L-lipoproteins with an elevated Apolipoprotein B. Despite these derangements, the patient did not exhibit any abdominal complaints, demonstrating a normal lipase level. The physical exam was indicative of bilateral arcus senilis and obesity. Insulin drip was initiated along with intravenous (IV) hydration and it required 12 days to bring triglycerides down to less than 1000 mg/dL. The total cholesterol was also seen to be down trending to around 500 mg/dL and the HDL improved to 22 mg/dL. We present this case as a unique presentation of asymptomatic chylomicronemia resistant to insulin treatment with an elevated ApoB but with no evidence of pancreatitis or coronary artery disease.

2023-05-11·Cureus

Acute Pancreatitis (AP) in Pregnancy and Its Complications From an Anesthesia Perspective: A Case Report

作者: Ghazzal, Samar ; Eldesokey, Ahmed ; Alanzi, Ahemd ; Adeel, Shahid ; Fouad, Amir

Acute pancreatitis (AP) is a rare event in pregnancy that is characterized by a sudden and severe inflammation of the pancreas. The clinical manifestation of AP during pregnancy is highly variable ranging from a mild form to a severe and potentially life-threatening presentation. We share a case of a 29-year-old female (gravida II, para I) who presented in her 33rd gestational week. The patient complained of upper abdominal pain and nausea. Her previous history revealed that she had four episodes of vomiting (food-containing, non-projectile) at home. Her uterine tone was normal, and her cervix was closed. Her white blood cell count was 13,000/mm³, and her C-reactive protein (CRP) level was 65 mg/L. She underwent an emergency laparotomy due to suspected acute appendicitis; however, no peritonitis was found intraoperatively. Further blood tests showed high levels of triglyceride at 87.5 mmol/L. The electrophoretic pattern of lipoprotein was consistent with type V hyperlipoproteinemia. An abdominal computed tomography (CT) confirmed the diagnosis of acute pancreatitis. During follow-up after one month, the patient showed triglyceride levels at 4.75 mmol/L and cholesterol at 6.07 mmol/L. Acute pancreatitis due to hypertriglyceridemia is a rare finding; nonetheless, it should be considered as a potential etiology in pregnant patients with nonobstructive abdominal pain.

2022-05-01·Internal Medicine4区 · 医学

Eruptive Xanthomas Caused by Primary Type V Hyperlipoproteinemia

4区 · 医学

Article

作者: Watanabe, Tsuyoshi ; Fujita, Yoshiro ; Takizawa, Naoho ; Nakamura, Yoshihiro